Swiss come onboard, but shunned EU GMP ‘standard’ may bring drug shortages
This article was originally published in Scrip
Executive Summary
As Switzerland becomes the first country to receive an "equivalence" rating from the European Commission for its regulations on active pharmaceutical ingredients (APIs), many of the biggest API manufacturing countries including India and China have still not even applied for an equivalence assessment.